- List
- By Topic
- On Map
- Search Details

Recruiting, Not yet recruiting, Available Studies | "Pancreatic Neoplasms"
Need help? See RSS Feeds
Choose a feed type:

Recruiting, Not yet recruiting, Available Studies | "Pancreatic Neoplasms" (602 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT02555735 | Recruiting | Exceptional Responders With Pancreatic Cancer to Chemotherapy |
|
|
Observational |
|
Industry / Other |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT02555735 | ADRL-003 | October 2015 | September 2017 | September 2018 | September 22, 2015 | October 20, 2015 |
|
|||
2 | NCT02869581 | Recruiting | Institut Paoli-Calmettes Pancreatic Neoplasms Database |
|
|
Observational |
|
Other |
|
|
8500 | All | 18 Years and older (Adult, Senior) | NCT02869581 | BDD-PANCREAS-IPC | January 2000 | January 2030 | December 2030 | August 17, 2016 | August 17, 2016 |
|
|||
3 | NCT03218345 | Recruiting | EUS-guided RFA for Pancreatic Neoplasms |
|
|
Interventional | Not Applicable |
|
Other |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT03218345 | CRE-2015.531T | August 2016 | May 2019 | May 2019 | July 14, 2017 | July 18, 2017 |
|
||
4 | NCT02896803 | Recruiting | Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
37 | All | 18 Years to 75 Years (Adult, Senior) | NCT02896803 | 869/15 | PanFLOX | August 2016 | August 2018 | August 2018 | September 12, 2016 | January 13, 2017 |
|
|
5 | NCT03310632 | Recruiting | Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
52 | All | 18 Years and older (Adult, Senior) | NCT03310632 | GHPanc-1-001 | December 1, 2017 | August 27, 2020 | August 27, 2020 | October 16, 2017 | December 4, 2017 |
|
||
6 | NCT03199144 | Recruiting | Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
70 | All | 18 Years and older (Adult, Senior) | NCT03199144 | Pancreas cancer neoadjuvant | CKPancreas | April 20, 2017 | December 2023 | December 2023 | June 26, 2017 | July 2, 2017 |
|
|
7 | NCT02043288 | Recruiting | Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer |
|
|
Interventional | Phase 3 |
|
Industry |
|
|
400 | All | 20 Years to 80 Years (Adult, Senior) | NCT02043288 | NC-6004-005 | January 2014 | March 2018 | March 2018 | January 23, 2014 | November 15, 2016 |
|
||
8 | NCT02726854 | Recruiting | Apatinib as Second-line Treatment of Advanced Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
30 | All | 18 Years to 70 Years (Adult, Senior) | NCT02726854 | XJTU1AF-CRF-2015-024 | Apslpanc | April 2016 | December 2017 | December 2017 | April 4, 2016 | December 2, 2016 |
|
|
9 | NCT02308722 | Recruiting | SBRT Pre-operatively for Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other |
|
|
24 | All | 16 Years and older (Child, Adult, Senior) | NCT02308722 | OCTO_054 18496 14138956 |
SPARC | April 2015 | January 2018 | January 2018 | December 4, 2014 | April 14, 2017 |
|
|
10 | NCT02737228 | Recruiting | Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
72 | All | 20 Years to 75 Years (Adult, Senior) | NCT02737228 | CG200745-2-03 | March 2016 | July 2018 | July 2018 | April 13, 2016 | December 14, 2017 |
|
||
11 | NCT03250078 | Recruiting | A Pancreatic Cancer Screening Study in High Risk Individuals Including Those With New-Onset Diabetes Mellitus |
|
|
Observational |
|
Other |
|
|
800 | All | 50 Years to 80 Years (Adult, Senior) | NCT03250078 | NH 16-17 | November 2016 | November 2021 | November 2023 | August 15, 2017 | August 15, 2017 |
|
|||
12 | NCT03264092 | Recruiting | Comparison of Three Tissue Acquiring Techniques During EUS Guided Biopsies of Solid Pancreatic Tumors. |
|
|
Interventional | Not Applicable |
|
Other |
|
|
300 | All | 18 Years to 80 Years (Adult, Senior) | NCT03264092 | E17118 | September 11, 2017 | October 31, 2018 | October 31, 2018 | August 28, 2017 | October 13, 2017 |
|
||
13 | NCT03316599 | Recruiting | Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
30 | All | 18 Years and older (Adult, Senior) | NCT03316599 | 17-406 | January 17, 2018 | November 30, 2020 | November 30, 2023 | October 20, 2017 | January 23, 2018 |
|
||
14 | NCT03435289 | Recruiting | A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
24 | All | 18 Years and older (Adult, Senior) | NCT03435289 | GA CPI 613 | October 19, 2017 | November 2018 | January 2019 | February 16, 2018 | February 16, 2018 |
|
||
15 | NCT01692873 | Recruiting | Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors |
|
|
Interventional | Not Applicable |
|
Other |
|
|
300 | All | 18 Years and older (Adult, Senior) | NCT01692873 | PACAomics / IPC 2011-004 | PACAomics | February 2012 | December 2017 | December 2017 | September 25, 2012 | June 21, 2017 |
|
|
16 | NCT03392571 | Not yet recruiting | Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients |
|
|
Interventional | Phase 2 |
|
Other |
|
|
70 | All | 18 Years to 75 Years (Adult, Senior) | NCT03392571 | PCRT 17-001 | February 15, 2018 | December 30, 2020 | December 30, 2020 | January 8, 2018 | January 8, 2018 | |||
17 | NCT02858141 | Recruiting | Onco-geriatric Database of Patients With Pancreatic Cancer |
|
|
Observational |
|
Other |
|
|
300 | All | 70 Years and older (Senior) | NCT02858141 | ONCOGEPAN | May 2015 | May 2020 | August 8, 2016 | August 8, 2016 |
|
||||
18 | NCT03180437 | Recruiting | Safety and Efficiency of γδ T Cell Against Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
30 | All | 18 Years to 75 Years (Adult, Senior) | NCT03180437 | Gd T cell and Pancreatic Ca | June 15, 2017 | June 15, 2018 | June 15, 2020 | June 8, 2017 | June 8, 2017 |
|
||
19 | NCT02318095 | Recruiting | Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
40 | All | 18 Years and older (Adult, Senior) | NCT02318095 | Pro00058865 | February 17, 2015 | January 2019 | January 2020 | December 17, 2014 | January 9, 2018 |
|
||
20 | NCT02767752 | Recruiting | Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
180 | All | 18 Years and older (Adult, Senior) | NCT02767752 | GI 1604 | CHIPAC | November 2016 | November 2019 | November 2021 | May 10, 2016 | November 11, 2016 |
|
|
21 | NCT02024009 | Recruiting | Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2 |
|
|
Interventional | Phase 1 Phase 2 |
|
Other / Industry |
|
|
289 | All | 18 Years and older (Adult, Senior) | NCT02024009 | OCTO_063 | SCALOP-2 | March 2016 | August 2020 | August 2020 | December 31, 2013 | July 6, 2017 |
|
|
22 | NCT02650804 | Recruiting | BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients |
|
|
Interventional | Phase 2 |
|
Industry |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT02650804 | BPM31510IV-05 | February 2016 | January 2019 | January 2019 | January 8, 2016 | March 19, 2018 |
|
||
23 | NCT03469726 | Recruiting | Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
465 | All | 18 Years and older (Adult, Senior) | NCT03469726 | NL60473.091.17 | DIA-PANC | December 22, 2017 | December 2019 | December 2019 | March 19, 2018 | March 19, 2018 |
|
|
24 | NCT03192462 | Recruiting | TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Other |
|
|
45 | All | 18 Years and older (Adult, Senior) | NCT03192462 | H-40378 TACTOPS | TACTOPS | January 18, 2018 | May 1, 2021 | November 1, 2025 | June 20, 2017 | February 2, 2018 |
|
|
25 | NCT03374293 | Recruiting | Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
21 | All | 18 Years to 75 Years (Adult, Senior) | NCT03374293 | HangzhouCH10 | December 1, 2017 | December 31, 2018 | December 31, 2018 | December 15, 2017 | December 15, 2017 |
|
||
26 | NCT02934984 | Recruiting | Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer |
|
Observational |
|
Other |
|
|
100 | All | 20 Years to 90 Years (Adult, Senior) | NCT02934984 | 2016-07-054 | July 2016 | July 2019 | January 2020 | October 17, 2016 | October 17, 2016 |
|
||||
27 | NCT02128100 | Recruiting | Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
28 | All | 18 Years and older (Adult, Senior) | NCT02128100 | BCC-RAD-13 IRB # 14.0XXX |
BCC-RAD-13 | May 2014 | May 2018 | May 2018 | May 1, 2014 | January 5, 2018 |
|
|
28 | NCT03060720 | Recruiting | Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy |
|
Observational |
|
Other / NIH |
|
|
375 | All | 18 Years and older (Adult, Senior) | NCT03060720 | 16-448 P50CA127003 |
February 24, 2017 | February 2020 | February 2022 | February 23, 2017 | February 1, 2018 |
|
||||
29 | NCT02734680 | Recruiting | IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
70 | All | 18 Years to 75 Years (Adult, Senior) | NCT02734680 | LC2015L11 | IFCSLAPC | February 2016 | February 2018 | February 2019 | April 12, 2016 | April 11, 2017 |
|
|
30 | NCT02894944 | Recruiting | Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other |
|
|
9 | All | 18 Years to 74 Years (Adult, Senior) | NCT02894944 | SNUBH-IMGPB-2016-02 | Theragene | August 2016 | July 2018 | July 2018 | September 9, 2016 | October 11, 2017 |
|
|
31 | NCT03187028 | Recruiting | Diet and Exercise After Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT03187028 | F141218007 | PACE | August 3, 2017 | August 31, 2018 | August 31, 2019 | June 14, 2017 | January 3, 2018 |
|
|
32 | NCT02981641 | Recruiting | IORT Versus CCRT for Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
100 | All | 18 Years to 75 Years (Adult, Senior) | NCT02981641 | 2012AA022701 | IVCPC | December 2015 | December 2016 | December 2018 | December 5, 2016 | December 5, 2016 |
|
|
33 | NCT03117920 | Recruiting | A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
35 | All | 18 Years and older (Adult, Senior) | NCT03117920 | Minnelide002 | MinPAC | April 10, 2017 | May 15, 2018 | February 15, 2019 | April 18, 2017 | September 14, 2017 |
|
|
34 | NCT03415802 | Recruiting | Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
60 | All | 18 Years to 75 Years (Adult, Senior) | NCT03415802 | CH-GI-062 | January 1, 2015 | March 1, 2018 | January 1, 2019 | January 30, 2018 | February 20, 2018 |
|
||
35 | NCT03189914 | Recruiting | RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer |
|
|
Interventional | Phase 1 Phase 2 |
|
Industry |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT03189914 | RX3117-003 | October 2, 2017 | December 2019 | July 2020 | June 16, 2017 | February 16, 2018 |
|
||
36 | NCT02089269 | Recruiting | Tumor Registry Pancreatic Cancer |
|
Observational |
|
Industry |
|
|
1650 | All | 18 Years and older (Adult, Senior) | NCT02089269 | iOM-01281 Tumorregister Pankreaskarzinom |
TPK | December 2013 | March 2020 | March 2020 | March 17, 2014 | March 22, 2018 |
|
|||
37 | NCT03264404 | Recruiting | Azacitidine and Pembrolizumab in Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other |
|
|
31 | All | 18 Years and older (Adult, Senior) | NCT03264404 | AAAR3554 | October 1, 2017 | March 2019 | September 2019 | August 29, 2017 | March 22, 2018 |
|
||
38 | NCT02900677 | Recruiting | Developing Prehabilitation Program in Patients With Operable Pancreatic Cancer Perioperatively and Following Surgery |
|
|
Interventional | Not Applicable |
|
Other |
|
|
168 | All | 20 Years to 80 Years (Adult, Senior) | NCT02900677 | 201505160RINB | August 2015 | July 2018 | July 2018 | September 14, 2016 | September 14, 2016 |
|
||
39 | NCT03311776 | Recruiting | BIOmarkers in Patients With Pancreatic Cancer ("BIOPAC") |
|
Observational |
|
Other |
|
|
5000 | All | 19 Years and older (Adult, Senior) | NCT03311776 | GI 0815 | BIOPAC | July 3, 2008 | July 2, 2035 | July 2, 2035 | October 17, 2017 | October 17, 2017 |
|
|||
40 | NCT02945267 | Not yet recruiting | Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer |
|
|
Interventional | Phase 4 |
|
Other |
|
|
60 | All | 18 Years to 75 Years (Adult, Senior) | NCT02945267 | PC20150423 | September 2016 | December 2018 | December 2019 | October 26, 2016 | October 26, 2016 |
|
||
41 | NCT02677038 | Recruiting | Olaparib for BRCAness Phenotype in Pancreatic Cancer |
|
|
Interventional | Phase 2 |
|
Other / Industry |
|
|
24 | All | 18 Years and older (Adult, Senior) | NCT02677038 | 2015-0503 NCI-2016-00351 |
November 11, 2016 | November 2019 | November 2020 | February 9, 2016 | February 28, 2018 |
|
||
42 | NCT03086642 | Recruiting | Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other / Industry |
|
|
16 | All | 18 Years and older (Adult, Senior) | NCT03086642 | AAAQ9966 | November 16, 2017 | April 2021 | April 2026 | March 22, 2017 | March 8, 2018 |
|
||
43 | NCT01989000 | Recruiting | The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome |
|
|
Interventional | Not Applicable |
|
Other |
|
|
95 | All | 18 Years and older (Adult, Senior) | NCT01989000 | NL45913.018.13 | MIPA | November 2013 | September 2017 | September 2017 | November 20, 2013 | July 27, 2016 |
|
|
44 | NCT02332863 | Recruiting | Comparison of Back-loaded vs Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement in Pancreatic Cancer. |
|
|
Interventional | Not Applicable |
|
Other / Industry |
|
|
40 | All | 18 Years and older (Adult, Senior) | NCT02332863 | 14-1711.cc | August 3, 2016 | April 2018 | April 2018 | January 7, 2015 | January 19, 2018 |
|
||
45 | NCT02555813 | Recruiting | Treatment of Pancreatic Cancer With Abraxane |
|
|
Observational |
|
Industry |
|
|
75 | All | 18 Years and older (Adult, Senior) | NCT02555813 | ABI-007-PANC-006 | May 8, 2015 | March 31, 2019 | July 31, 2019 | September 22, 2015 | January 29, 2018 |
|
|||
46 | NCT02873598 | Recruiting | A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer |
|
|
Interventional | Phase 1 |
|
Other |
|
|
34 | All | 18 Years to 99 Years (Adult, Senior) | NCT02873598 | 16-1139.cc | November 29, 2016 | August 2019 | August 2019 | August 19, 2016 | March 23, 2018 |
|
||
47 | NCT02080221 | Recruiting | BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial |
|
|
Interventional | Phase 2 |
|
Other |
|
|
50 | All | 18 Years and older (Adult, Senior) | NCT02080221 | BrUOG 292 | August 2014 | September 2018 | December 2018 | March 6, 2014 | December 13, 2017 |
|
||
48 | NCT02117895 | Recruiting | Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail |
|
|
Interventional | Phase 3 |
|
Other |
|
|
180 | All | 18 Years to 80 Years (Adult, Senior) | NCT02117895 | PCI002 | January 2014 | January 2017 | January 2017 | April 21, 2014 | August 11, 2016 |
|
||
49 | NCT02416609 | Recruiting | Low-dose Radiotherapy Plus Chemotherapy With GemOx and Stereotactic Radiotherapy for Advanced Pancreatic Cancer |
|
|
Interventional | Not Applicable |
|
Other |
|
|
22 | All | 18 Years and older (Adult, Senior) | NCT02416609 | BMed1 | ORCHESTRATE | January 2014 | November 2018 | November 2019 | April 15, 2015 | October 13, 2017 |
|
|
50 | NCT02041936 | Recruiting | Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System |
|
|
Interventional | Not Applicable |
|
Other |
|
|
12 | All | 18 Years and older (Adult, Senior) | NCT02041936 | HP-00052144 | April 2014 | December 2019 | December 2019 | January 22, 2014 | August 24, 2017 |
|
† Study has passed its completion date and status has not been verified in more than two years.